8-K: Alaunos Therapeutics Implements 1-for-15 Reverse Stock Split

Alaunos Therapeutics has completed a 1-for-15 reverse stock split, effective January 31, 2024, to consolidate its shares.

Summary

• Alaunos Therapeutics, Inc. has filed a Second Amended and Restated Certificate of Incorporation to enact a 1-for-15 reverse stock split.
• The reverse stock split was approved by stockholders at the Annual Meeting on June 6, 2023.
• The Board of Directors determined the final ratio of 1-for-15 on January 12, 2024, within the previously approved range of 1-for-5 to 1-for-15.
• The reverse split became effective on January 31, 2024, at 5:00 p.m. Eastern Time.
• Every 15 shares of common stock were combined into 1 share.
• Trading on the Nasdaq Capital Market will continue under the symbol TCRT on a split-adjusted basis starting February 1, 2024, with a new CUSIP number 98973P200.
• Equiniti Trust Company is the exchange agent and will provide instructions to stockholders for exchanging pre-split shares for post-split shares.
• Fractional shares will not be issued; instead, shareholders will receive cash equal to the fraction multiplied by the closing price on the day before the effective time.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, as it primarily describes a corporate action (reverse stock split) that is neither inherently positive nor negative. The action is expected and does not indicate any significant change in the company's financial health or future prospects.

Positives

• The reverse stock split was previously approved by stockholders, indicating shareholder support.
• The company has engaged an exchange agent to facilitate the process for stockholders.

Risks

• Reverse stock splits can sometimes be perceived negatively by the market, potentially impacting investor confidence.
• The company's share price may experience volatility following the reverse split.

Future Outlook

The company will continue to trade on the Nasdaq Capital Market under the symbol TCRT on a split-adjusted basis.

Management Comments

• The Board of Directors determined the final ratio of the reverse stock split.

Industry Context

Reverse stock splits are often used by companies to increase their stock price and maintain listing requirements on exchanges like Nasdaq. This action is not uncommon in the biotechnology sector, where companies may need to raise capital or improve their market perception.

Comparison to Industry Standards

• Many companies in the biotechnology sector, particularly those with lower share prices, have used reverse stock splits to meet minimum listing requirements or to make their stock more attractive to institutional investors.
• For example, companies like Agenus Inc. and Ocugen Inc. have also recently implemented reverse stock splits to maintain their Nasdaq listing.
• The 1-for-15 ratio is within the typical range for reverse stock splits, which can vary from 1-for-2 to 1-for-20 or more.

Stakeholder Impact

• Shareholders will have fewer shares, but each share will represent a larger portion of the company.
• Shareholders will receive cash in lieu of fractional shares.
• The reverse stock split may impact the perceived value of the company's stock.

Next Steps

• Stockholders will receive instructions from Equiniti Trust Company on how to exchange their pre-split shares for post-split shares.
• The company will begin trading on a split-adjusted basis on February 1, 2024.

Key Dates

Keywords

reverse stock split, stock consolidation, TCRT, Alaunos Therapeutics, shareholder, Nasdaq, CUSIP, Equiniti